Company Overview and News

 
ASX:AXP / AIRXPANDERS, INC. FORM 8-K (Current Report)

7h sec.gov
axp20170720_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C.

 
ASX:AXP / AIRXPANDERS, INC. FORM 10-Q (Quarterly Report)

2018-05-03 sec.gov
axp20170731_10q.htm

 
ASX:AXP / AIRXPANDERS, INC. FORM S-8

2018-05-03 sec.gov
axp20170809_s8.htm As filed with the Securities and Exchange Commission on May 3, 2018 Registration No. 333-

 
ASX:AXP / AIRXPANDERS, INC. FORM 8-K (Current Report)

2018-05-02 sec.gov
axp20170720_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C.

 
ASX:AXP / AIRXPANDERS, INC. FORM DEF 14A

2018-05-01 sec.gov
axpd20171120_def14a.htm SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 
ASX:AXP / AIRXPANDERS, INC. FORM 8-K (Current Report)

2018-04-27 sec.gov
axp20170720_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C.

 
ASX:AXP / AIRXPANDERS, INC. FORM 8-K (Current Report)

2018-04-20 sec.gov
axp20170720_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C.

 
ASX:AXP / AIRXPANDERS, INC. FORM PRE 14A

2018-04-20 sec.gov
axpd20171120_def14a.htm SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 
ASX:AXP / AIRXPANDERS, INC. FORM 8-K (Current Report)

2018-04-11 sec.gov
axp20170720_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C.

 
ASX:AXP / AIRXPANDERS, INC. FORM 8-K (Current Report)

2018-04-09 sec.gov
axp20170720_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C.

 
ASX:AXP / AIRXPANDERS, INC. FORM 10-K (Annual Report)

2018-02-28 sec.gov
axp20170613_1012ga.htm

 
ASX:AXP / AIRXPANDERS, INC. FORM 8-K (Current Report)

2018-02-20 sec.gov
axp20170720_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   February 13, 2018   Date of Report (date of earliest event reported)   AirXpanders, Inc. (Exact name of Registrant as specified in charter)   Delaware   000-55781   20-2555438 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.

 
ASX:AXP / AIRXPANDERS, INC. / Greencape Capital Pty Ltd - 13G (Passive Investment)

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. )* AirXpanders, Inc. (Name of Issuer)   Class A Common Stock, $0.001 par value (Title of Class of Securities)   N/A (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d)    

 
AXP / AIRXPANDERS, INC. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-13 fintel.io
AIRXPANDERS, INC. (ASX:AXP) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12,878,216 shares. Largest shareholders include Greencape Capital Pty Ltd, and Prolog Capital Ii Lp.

 
ASX:AXP / AIRXPANDERS, INC. / Greencape Capital Pty Ltd - 13G (Passive Investment)

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. )* AirXpanders, Inc. (Name of Issuer)   Class A Common Stock, $0.001 par value (Title of Class of Securities)   N/A (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d)    

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...